Valuation : Annexon, Inc.

Market Cap 93Cr 81Cr 76Cr 69Cr 129.35Cr 8.83TCr 130.32Cr 899.24Cr 348.99Cr 4.51TCr 350.96Cr 343.29Cr 15TCr P/E 2026 *
-4.75x
P/E 2027 * -5.04x
Enterprise Value 84Cr 73Cr 69Cr 62Cr 116.82Cr 7.97TCr 117.7Cr 812.12Cr 315.18Cr 4.08TCr 316.96Cr 310.03Cr 13TCr EV / Sales 2026 *
-
EV / Sales 2027 * 21.9x
Free-Float
94.44%
Yield 2026 *
-
Yield 2027 * -
1 day-0.61%
1 week-6.00%
Current month-0.10%
1 month-6.00%
3 months-8.44%
6 months-9.12%
Current year-1.69%
1 week 4.78
Extreme 4.78
5.2
1 month 4.78
Extreme 4.78
5.7
Current year 4.46
Extreme 4.46
7.18
1 year 2.04
Extreme 2.04
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
23.61
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 01/12/2014
Director of Finance/CFO 53 01/06/2019
Chief Tech/Sci/R&D Officer 68 27/07/2023
Director TitleAgeSince
Director/Board Member 58 01/12/2014
Director/Board Member 67 05/02/2021
Director/Board Member 56 01/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/08/26 Free

Director

1,75,000 0.0923%
28/05/26
Alerce Investment Management LP
BuyCompany 6,13,497 0.3775%
11/05/26 Buy

Director

8,000 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
-0.91%-6.00%+140.73%+84.14% 93Cr
+1.03%-2.05%+39.28%+94.60% 6.89TCr
+0.93%+0.29%+49.08%+91.62% 6.53TCr
-0.62%+3.75%-12.24%+377.59% 2.77TCr
+2.97%-0.10%+41.86%+14.84% 2.58TCr
-1.05%-7.94%+2.12%-15.94% 2.61TCr
+1.33%+1.75%+26.94%-17.20% 2.01TCr
+3.45%-14.83%+225.22%+389.50% 1.7TCr
+0.77%-4.55%-0.36%+549.41% 1.5TCr
+1.01%+6.79%+59.66%+164.98% 1.45TCr
Average +0.95%-2.51%+57.23%+173.35% 2.81TCr
Weighted average by Cap. +1.02%-2.12%+42.92%+141.91%

Financials

2026 *2027 *
Net sales - 3.89Cr 3.36Cr 3.16Cr 2.88Cr 5.39Cr 367.63Cr 5.43Cr 37Cr 15Cr 187.96Cr 15Cr 14Cr 617.43Cr
Net income -21Cr -18Cr -17Cr -16Cr -29Cr -2TCr -30Cr -203.63Cr -79Cr -1.02TCr -79Cr -78Cr -3.36TCr -21Cr -18Cr -17Cr -16Cr -29Cr -1.98TCr -29Cr -201.41Cr -78Cr -1.01TCr -79Cr -77Cr -3.32TCr
Net Debt -9.05Cr -7.81Cr -7.36Cr -6.7Cr -13Cr -855.37Cr -13Cr -87Cr -34Cr -437.33Cr -34Cr -33Cr -1.44TCr -8.07Cr -6.96Cr -6.56Cr -5.98Cr -11Cr -762.4Cr -11Cr -78Cr -30Cr -389.79Cr -30Cr -30Cr -1.28TCr
Logo Annexon, Inc.
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Employees
92
Date Price Change Volume
03/26/03 $4.935 +0.10% 2,37,770
02/26/02 $4.930 +0.82% 18,42,212
01/26/01 $4.890 -1.01% 14,72,605
31/26/31 $4.940 -0.60% 24,36,868
28/26/28 $4.970 -5.33% 16,18,594
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.930USD
Average target price
15.29USD
Spread / Average Target
+210.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANNX Stock